Table 6 KEGG analysis of differentially expressed genes
Term | ID | Description | Adj.P.Val | Count |
|---|---|---|---|---|
OA-specific | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 7.94E-06 | 27 |
hsa04120 | Ubiquitin mediated proteolysis | 7.94E-06 | 38 | |
hsa04068 | FoxO signaling pathway | 1.88E-05 | 36 | |
hsa04012 | ErbB signaling pathway | 2.08E-05 | 27 | |
hsa05215 | Prostate cancer | 2.59E-05 | 29 | |
hsa04910 | Insulin signaling pathway | 9.18E-05 | 35 | |
hsa04350 | TGF-beta signaling pathway | 1.10E-04 | 27 | |
hsa04931 | Insulin resistance | 1.53E-04 | 29 | |
hsa05205 | Proteoglycans in cancer | 1.53E-04 | 45 | |
RA-specific | hsa04068 | FoxO signaling pathway | 2.39E-05 | 33 |
hsa04350 | TGF-beta signaling pathway | 3.84E-05 | 26 | |
hsa01521 | EGFR tyrosine kinase inhibitor resistance | 3.84E-05 | 23 | |
hsa04012 | ErbB signaling pathway | 3.84E-05 | 24 | |
hsa04120 | Ubiquitin mediated proteolysis | 1.12E-04 | 31 | |
hsa04510 | Focal adhesion | 1.12E-04 | 40 | |
hsa04931 | Insulin resistance | 2.05E-04 | 26 | |
hsa04151 | PI3K-Akt signaling pathway | 2.23E-04 | 59 | |
hsa05215 | Prostate cancer | 2.23E-04 | 24 |